Quarterly report · Q1
4671.TEDINET S100OZLA
Period2022-04-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥11.6bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥50.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.0bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥681m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥1.3bn | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥769m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥748m | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.3bn | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥442m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥845m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥442m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥845m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥38.2bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥40.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥37.7bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥14.6bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥16.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥23.6bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥23.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥21.0bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.6bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥42.32 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥339 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥81.41 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥42.25 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥336.99 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥81.28 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 61.5% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.1% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.5% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥4m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥108m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥7.7bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥7.7bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥782m |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥3.9bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥3.9bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥0 |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥6m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥11.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥11.6bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥4m |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥789m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥4m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥84m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥8.0bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥8.0bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥3m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥4.0bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥4.0bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥0 |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥102m |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥12.0bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥12.0bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥4m |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥1.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 352
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 4000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -4000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 7678000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 3891000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 11570000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -4000000 | JPY |
| Net sales | CurrentYTDDuration | 11566000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 782000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 6000000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 789000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -108000000 | JPY |
| Operating income | CurrentYTDDuration | 681000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)近畿財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-08-10 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第36期第１四半期（自 令和４年４月１日 至 令和４年６月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社ファルコホールディングス | |
| Company name in english cover page | FilingDateInstant | FALCO HOLDINGS Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 安田 忠史 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)京都市左京区聖護院蓮華蔵町44番地３（同所は登記上の本店所在地で実際の管理業務は「最寄りの連絡場所」で行っております。） | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | － | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | － | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)大阪市中央区内平野町１丁目３番７号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | ０６－７６３２－６１５０ | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)執行役員管理室長 大馬 久幸 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E04982 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 46710 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社ファルコホールディングス | |
| Filer name in english | FilingDateInstant | FALCO HOLDINGS Co., Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Current period end date | FilingDateInstant | 2022-06-30 | |
| Type of current period | FilingDateInstant | Q1 | |
| Current fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2021-04-01 | |
| Comparative period end date | FilingDateInstant | 2021-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2022-03-31 | |
| Next fiscal year start date | FilingDateInstant | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |